Pathstone Family Office adds Merck & Co. (MRK) to its portfolio

Merck & Co. (MRK) : Pathstone Family Office added new position in Merck & Co. during the most recent quarter end. The investment management firm now holds 14,270 shares of Merck & Co. which is valued at $768,868 , the company said in a statement filed on May 12, 2016 with the SEC.Merck & Co. makes up approximately 0.06% of Pathstone Family Office’s portfolio.

Other Hedge Funds, Including , Hanlon Investment Management sold out all of its stake in MRK during the most recent quarter. The investment firm sold 75,162 shares of MRK which is valued $4 Million.Nations Financial Group Inc Ia Adv reduced its stake in MRK by selling 972 shares or 7.89% in the most recent quarter. The Hedge Fund company now holds 11,346 shares of MRK which is valued at $611,322. Merck & Co. makes up approx 0.70% of Nations Financial Group Inc Ia Adv’s portfolio.Independent Franchise Partners Llp reduced its stake in MRK by selling 138,651 shares or 1.41% in the most recent quarter. The Hedge Fund company now holds 9,672,103 shares of MRK which is valued at $521.1 Million. Merck & Co. makes up approx 5.92% of Independent Franchise Partners Llp’s portfolio.Boston Financial Mangement Inc reduced its stake in MRK by selling 2,136 shares or 1.47% in the most recent quarter. The Hedge Fund company now holds 143,458 shares of MRK which is valued at $7.7 Million. Merck & Co. makes up approx 1.15% of Boston Financial Mangement Inc’s portfolio.

Merck & Co. opened for trading at $54.83 and hit $55.54 on the upside on Friday, eventually ending the session at $55.11, with a gain of 0.97% or 0.53 points. The heightened volatility saw the trading volume jump to 86,33,110 shares. Company has a market cap of $152,546 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.